SR One Capital Management, LP reported 14 positions worth $1.01B for the quarter ended Jun 30, 2026, up 10.6% on the prior quarter. It opened 2 new positions, added to 1, trimmed 0 and exited 2. Its largest holding is Veradermics, Inc at 29.2% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | MANE Veradermics, Inc | Healthcare | 2.40M | $295.29M | 29.17% | 0 | 0.0% | Unchanged | 5.75% |
| 2 | ZBIO Zenas BioPharma, Inc. | Healthcare | 5.04M | $127.86M | 12.63% | 0 | 0.0% | Unchanged | 7.95% |
| 3 | CRSP CRISPR Therapeutics AG | Healthcare | 2.04M | $111.19M | 10.98% | 0 | 0.0% | Unchanged | 2.11% |
| 4 | AVLN Avalyn Pharma Inc. | Healthcare | 3.31M | $108.92M | 10.76% | +3.31M | – | New | 7.46% |
| 5 | DSGN Design Therapeutics, Inc. | Healthcare | 6.53M | $94.44M | 9.33% | 0 | 0.0% | Unchanged | 10.43% |
| 6 | ODTX Odyssey Therapeutics, Inc. | Healthcare | 3.79M | $71.00M | 7.01% | +3.79M | – | New | 7.92% |
| 7 | ALMS Alumis Inc. | Healthcare | 1.96M | $55.15M | 5.45% | 0 | 0.0% | Unchanged | 1.53% |
| 8 | ORIC Oric Pharmaceuticals, Inc. | Healthcare | 4.62M | $49.98M | 4.94% | +100.5K | +2.2% | Added | 4.27% |
| 9 | MLYS Mineralys Therapeutics, Inc. | Healthcare | 1.56M | $42.20M | 4.17% | 0 | 0.0% | Unchanged | 1.77% |
| 10 | SPRY ARS Pharmaceuticals, Inc. | Healthcare | 4.01M | $32.14M | 3.17% | 0 | 0.0% | Unchanged | 4.04% |
| 11 | NKTX Nkarta, Inc. | Healthcare | 3.33M | $9.43M | 0.932% | 0 | 0.0% | Unchanged | 4.47% |
| 12 | OCS Oculis Holding AG | Healthcare | 641.0K | $8.89M | 0.878% | 0 | 0.0% | Unchanged | 1.23% |
| 13 | RARE Ultragenyx Pharmaceutical Inc. | Healthcare | 137.8K | $4.60M | 0.454% | 0 | 0.0% | Unchanged | 0.14% |
| 14 | ENGN enGene Therapeutics Inc. | Healthcare | 747.8K | $1.29M | 0.128% | 0 | 0.0% | Unchanged | 1.07% |
Tip. Select a row to see that position’s full history at Sr One Capital Management.
As of its Q2 2026 13F filing, SR One Capital Management, LP’s five largest positions were Veradermics, Inc (MANE) at 29.2%, Zenas BioPharma, Inc. (ZBIO) at 12.6%, CRISPR Therapeutics AG (CRSP) at 11.0%, Avalyn Pharma Inc. (AVLN) at 10.8%, Design Therapeutics, Inc. (DSGN) at 9.3% of the reported portfolio.
SR One Capital Management, LP reported a 13F portfolio worth $1.01B across 14 positions for Q2 2026. That is up 10.6% from the previous quarter.
Its largest purchases by value were Avalyn Pharma Inc. ($108.92M), Odyssey Therapeutics, Inc. ($71.00M), Oric Pharmaceuticals, Inc. ($1.09M). It opened 2 new positions.
Its largest sales by value were GILEAD SCIENCES INC- CVR CONTINGENT VALUE RIGHT ($269.44M), Oruka Therapeutics, Inc. ($21.11M). It exited 2 positions entirely.
From the Form 13F-HR reports SR One Capital Management, LP files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.